Compare MVBF & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MVBF | TNXP |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.7M | 231.3M |
| IPO Year | N/A | N/A |
| Metric | MVBF | TNXP |
|---|---|---|
| Price | $27.79 | $19.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $27.60 | ★ $70.00 |
| AVG Volume (30 Days) | 74.4K | ★ 761.3K |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 73.99 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $167,853,000.00 | $10,299,000.00 |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | $14.06 | $933.49 |
| P/E Ratio | $11.37 | ★ N/A |
| Revenue Growth | ★ 18.75 | N/A |
| 52 Week Low | $15.59 | $6.76 |
| 52 Week High | $28.72 | $130.00 |
| Indicator | MVBF | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 56.16 |
| Support Level | $26.52 | $18.59 |
| Resistance Level | $28.72 | $20.24 |
| Average True Range (ATR) | 0.69 | 1.29 |
| MACD | 0.12 | 0.60 |
| Stochastic Oscillator | 72.70 | 81.63 |
MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.